title: Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.
abstract: Progress in cancer biology has led to an increasing discovery of oncogenic alterations of the platelet-derived growth factor receptors (PDGFRs) in cancers. In addition, their overexpression in numerous cancers invariably makes PDGFRs and platelet-derived growth factors (PDGFs) prognostic and treatment markers in some cancers. The oncologic alterations of the PDGFR/PDGF system affect the extracellular, transmembrane and tyrosine kinase domains as well as the juxtamembrane segment of the receptor. The receptor is also involved in fusions with intracellular proteins and receptor tyrosine kinase. These discoveries undoubtedly make the system an attractive oncologic therapeutic target. This review covers elementary biology of PDGFR/PDGF system and its role as a prognostic and treatment marker in cancers. In addition, the multifarious therapeutic targets of PDGFR/PDGF system are discussed. Great potential exists in the role of PDGFR/PDGF system as a prognostic and treatment marker and for further exploration of its multifarious therapeutic targets in safe and efficacious management of cancer treatments.
authors.affiliation: Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, People's Republic of China. kappiah@uds.ed.gh.|Department of Applied Biology, University for Development Studies, Navrongo, Ghana. kappiah@uds.ed.gh.
authors.forename: Kwaku
authors.initials: K
authors.lastname: Appiah-Kubi
authors.affiliation: Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, People's Republic of China.
authors.forename: Hai
authors.initials: H
authors.lastname: Qian
authors.affiliation: Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, People's Republic of China.
authors.forename: Min
authors.initials: M
authors.lastname: Wu
authors.affiliation: Basic Medical Department, Changchun Medical college, Changchun, Jilin, 130013, People's Republic of China.
authors.forename: Xiaoyuan
authors.initials: X
authors.lastname: Yao
authors.affiliation: Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, People's Republic of China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Physiology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212013, People's Republic of China. ycchen54@ujs.edu.cn.
authors.forename: Yongchang
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D052158:Aptamers, Peptide / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D002986:Clinical Trials as Topic; D016903:Drug Monitoring; D006801:Humans; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000032:analysis* / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000502:physiology; D009369:Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000628:therapy; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors / Q000235:genetics; D010982:Platelet-Derived Growth Factor / Q000032:analysis* / Q000737:chemistry / Q000502:physiology; D011379:Prognosis; D020033:Protein Isoforms / Q000032:analysis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D034622:RNA Interference; D017479:Receptors, Platelet-Derived Growth Factor / Q000032:analysis* / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000502:physiology; D015398:Signal Transduction; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D052158:Aptamers, Peptide; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D010982:Platelet-Derived Growth Factor; D020033:Protein Isoforms; D047428:Protein Kinase Inhibitors; D017479:Receptors, Platelet-Derived Growth Factor
keywords: Gene therapy; Immunotherapy; PDGFR/PDGF system; Prognostic marker; Small molecules; Therapeutic targets; Treatment response biomarker